Current overview and treatment of mantle cell lymphoma [version 1; referees: 3 approved]

Authors :: Michael Schieber
Leo I. Gordon
Reem Karmali
Author Affiliations :: <relatesTo>1</relatesTo>Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
Source :: F1000Research. 7:F1000 Faculty Rev-1136
Publication Year :: 2018
Publisher :: London, UK: F1000 Research Limited, 2018.
Abstract: Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma with historically poor long-term survival compared with other B-cell malignancies. Treatment strategies for this disease are variable and dependent on symptoms and patient fitness. Despite recent advances, MCL remains incurable and patients with high-risk disease have particularly poor outcomes. This review focuses on recent developments that enhance our understanding of the biology of MCL and new treatment approaches that have led to substantial improvements in clinical outcomes. We will outline induction immuno-chemotherapy and maintenance strategies in transplant-eligible patients. In addition, effective strategies for patients unfit for intensive induction will be discussed, with a particular focus on novel molecular therapies with activity in MCL. Lastly, a number of ongoing clinical trials will be presented; the data from these trials are anticipated to redefine standards of care in the near future.

Subjects :: Review
Articles
Mantle Cell Lymphoma
Management
Treatment
Diagnosis
Clinical trials

ISSN :: 20461402
Volume :: 7
Database :: F1000Research
Journal :: F1000Research
Notes :: Editorial Note on the Review Process F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version). The referees who approved this article are: Andre H. Goy, Lymphoma Division, John Theurer Cancer Center, Hackensack, New Jersey, USA No competing interests were disclosed. Jonathon B. Cohen, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA No competing interests were disclosed. Vincent Ribrag, Chairman of DITEP multidisciplinary committee and Chief of Molecular therapeutics in hematological early drug development, Gustave Roussy Comprehensive Cancer Center, Villejuif, France No competing interests were disclosed., , [version 1; referees: 3 approved]
Publication Type :: Academic Journal
Accession number :: edsfor.10.12688.f1000research.14122.1
Document Type :: review
Full Text :: https://doi.org/10.12688/f1000research.14122.1

Full Text Access

Tools